Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

This study is testing a four-drug combination — isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone — for people with multiple myeloma (a blood cancer affecting plasma cells) whose disease has come back or stopped responding to previous treatments. Each of these drugs targets myeloma cells through different mechanisms, and the combination is being tested to see if it can produce deeper and longer-lasting responses. **You may be eligible if:** - You are 18 years or older - You have been diagnosed with multiple myeloma that has relapsed or is no longer responding to treatment - You have received at least one prior line of therapy, including both lenalidomide and a proteasome inhibitor (such as bortezomib or carfilzomib) - Your disease has progressed within 60 days of your last treatment - You have measurable disease detectable by blood, urine, or free light chain tests - Your blood counts and organ function are within acceptable ranges (with some flexibility) **You may NOT be eligible if:** - You have significant organ impairment that makes the treatment unsafe - You are unable to tolerate any of the four drugs in the combination - You do not meet the required blood count minimums at screening Talk to your doctor to see if this trial is right for you.